Tracking Hepitype Evolution in Tumors Using Microdroplet PCR Sequencing
Author Information
Author(s): Alexander Herrmann, Andrea Haake, Ole Ammerpohl, Idoia Martin-Guerrero, Karol Szafranski, Kathryn Stemshorn, Michael Nothnagel, Steve K. Kotsopoulos, Julia Richter, Jason Warner, Jeff Olson, Darren R. Link, Stefan Schreiber, Michael Krawczak, Matthias Platzer, Peter Nürnberg, Reiner Siebert, Jochen Hampe
Primary Institution: Christian-Albrechts University, Kiel, Germany
Hypothesis
Can microdroplet PCR-based sequencing effectively track DNA methylation changes in tumors?
Conclusion
The study successfully demonstrates a novel pipeline for assessing DNA sequence variation and methylation in tumors with high coverage and accuracy.
Supporting Evidence
- The pipeline achieved an average coverage of 95% for the target sequences.
- Correlation with pyrosequencing data showed a Spearman correlation coefficient of 0.87.
- The method allows for the analysis of DNA methylation phylogeny in cancer.
- The study identified 2017 differentially methylated CpG sites.
Takeaway
This study shows a new way to look at how DNA changes in cancer by checking both the sequence and the chemical tags on it.
Methodology
The study used microdroplet PCR to analyze bisulfite-treated DNA for methylation and sequence variation across targeted genomic regions.
Limitations
The biological conclusions drawn from the limited dataset should be viewed with caution.
Participant Demographics
The study included samples from a 65-year-old male colon cancer patient and a 60-year-old female patient with follicular lymphoma.
Statistical Information
P-Value
p<1.0×10−15
Statistical Significance
p<1.0×10−15
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website